Tessa Therapeutics is a clinical-stage biotechnology company developing a portfolio of novel next-generation cell therapies for cancer.
CD30 is well validated target for treatment of CD30+ lymphomas, and is homogenously expressed in Classical Hodgkin Lymphoma and subsets of non-Hodgkin Lymphomas. Tessa’s approach to target CD30-positive cancers using CAR-T (Chimeric Antigen Receptor) cells has demonstrated excellent safety and efficacy in early clinical trials. Having received the RMAT and PRIME designation, Tessa is now advancing the therapy to a pivotal trial.
Off-the-shelf, allogeneic cell therapy has significant advantages and is the next frontier in cancer treatment. Tessa is developing a unique and potentially transformational allogeneic CD30-CAR EBVST platform capable of targeting a broad range of cancers. This platform is based on decades-long research and development by our Scientific Co-Founder, Dr. Malcolm Brenner, and his team at Baylor College of Medicine, and multiple clinical studies showing, strong safety profile and early signs of efficacy of Allogeneic Virus-Specific T cells (VSTs). CD30-CAR has shown to potentially have complementary properties, to further improve the performance of these cells.
Tessa is proud to be innovators in the field of cancer immunotherapy and remain committed to making a difference in the lives of cancer patients worldwide. Our global headquarters are in Singapore, where we are building our own state-of-the-art commercial manufacturing facility. We are also currently setting up our United States headquarters in New Jersey.
Malcolm K. Brenner,
Scientific Co-Founder & Advisor
Our T cell therapies harness the power of the immune system, train it to recognize cancer cells and eliminate them. Building on this scientific platform, Tessa Therapeutics is developing a portfolio of next-generation autologous and allogeneic cell therapies by combining T cells with other immuno-oncology approaches.
We are also creating a novel, allogeneic platform technology by integrating the properties of CD30-Chimeric Antigen Receptors (CD30-CARs) and Virus-Specific T cells in an allogeneic setting. This technology has the potential to create next-generation, off-the-shelf cell therapies to fight against a wider range of hematological malignancies and solid tumors. At its core, Epstein Barr Virus Specific T Cells (EBVSTs) are augmented with CD30-CARs technology to increase efficacy – and encouraging preclinical/early clinical data demonstrate the promise of this scientific approach.
Our clinical pipeline includes two innovative cell therapy platforms: CD30-CARs and VSTs. Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphoma.
Building robust, scalable operational capabilities is a critical aspect of our strategy to rapidly and reliably deliver cell therapies to patients worldwide.
Bolstered by a global production and supply chain footprint and a strong clinical trial network, our cell therapies have been delivered to patients in 30 clinical sites across 5 countries. To date, we have successfully delivered over 150 autologous cell therapies in a Phase III clinical trial setting.
Tessa Therapeutics plans to open a 90,000 square foot commercial-scale cell therapy manufacturing facility in 2021. Located in Singapore, it will be one of the leading facilities of its kind in Asia. The state-of-the-art facility is designed to fulfil multiple cell therapy trials on a global scale.
The facility will run both clinical and commercial manufacturing of cell therapy products that are compliant with current Good-Manufacturing-Practice (cGMP) guidelines from the U.S. Food and Drug Administration, European Medicines Agency and key regulators in Asia.
Clinical Trial Network
Together with our academic, clinical, and scientific research partners, we have established a fully integrated approach for the treatment of cancer with immunotherapy.
Our clinical trial partners include leading institutions in the United States, such as the Baylor College of Medicine, Stanford Cancer Institute, City of Hope National Medical Center, UCSF Medical Center, Baylor Scott & White Health, as well as other Centers of Excellence in Massachusetts, Texas, and California.